Vaccine-Preventable Disease
Measles Vaccines
Prevention and Treatment
Immunology
Pathogenesis
Virology
Q&A: Will Moderna's mRNA RSV vaccine increase uptake next respiratory virus season?
In late May, the FDA announced approval of Moderna's mResvia, marking the third vaccine approved for respiratory syncytial virus and first time messenger RNA technology has been used for preventing a disease other than COVID-19.
Survey shows low RSV vaccine uptake among older adults in the US
A recent survey showed that only about one-quarter of older adults have received respiratory syncytial virus vaccinations.
Multiple RSV vaccines in late-stage development show promise in older adults
WASHINGTON — Three late-breaking studies offered a promising glimpse of respiratory syncytial virus vaccines in the pipeline for older adults — including the RSVPreF3 OA vaccine, which showed an overall vaccine efficacy of about 83%.
FDA authorizes Moderna, Pfizer’s bivalent omicron boosters for children, adolescents
The FDA has granted an emergency use authorization for booster doses of Moderna and Pfizer-BioNTech’s omicron BA.4/BA.5-adapted bivalent COVID-19 vaccines for children and adolescents, both companies announced today.
CDC launches monkeypox vaccine equity program
The CDC on Thursday launched a monkeypox vaccine equity pilot program to reach more of the populations that are most at risk for infection.